Rapid advancements in the area of early cancer detection have brought us closer to
achieving the goals of finding cancer early enough to treat or cure it, while avoiding harms of …

Until recently the application of artificial intelligence (AI) in precision oncology was confined
to activities in drug development and had limited impact on the personalisation of therapy …

Background Multicancer early detection (MCED) blood tests can detect a cancer signal from
circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study …

Background A rapid, low-cost blood test that can be applied to reliably detect multiple
different cancer types would be transformational. Methods In this large-scale discovery study …

Abstract Circulating tumor DNA (ctDNA, DNA shed by cancer cells) is emerging as one of
the most transformative cancer biomarkers discovered to-date. Although potentially useful at …

Background Understanding relationships between presenting symptoms and subsequently
diagnosed cancers can inform symptom awareness campaigns and investigation strategies …

Objective Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an
advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC …

Background High ovarian cancer mortality rates motivate the development of effective and
patient-friendly diagnostics. Here, we explored the potential of molecular testing in patient …

The rising utilization of circulating tumor DNA (ctDNA) assays in Precision Oncology may
incidentally detect genetic material from secondary sources. It is important that such findings …

Background To detect uterine cancer, simpler and more specific index tests are needed to
triage women with abnormal uterine bleeding to a reference histology test. We aimed to …